HIGHLIGHTS
- who: Michal Grzmil et al. from the Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland have published the paper: Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer, in the Journal: Cancers 2023, 15, 17. of /2023/
- future: These findings sugand further research is is less needed to provide of the effectiveness of metformin gest that metformin potent in_vivoevidence and further research is needed to providetreateviment in withofRLT.
SUMMARY
Targeted radionuclide therapy (TRT), such as radioligand therapy (RLT), represents another treatment strategy using ionizing_radiation for spread cancer lesions . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.